Table 3

Phenotype and mutations in COACH subjects reported in the literature

ReferenceMutations*Amino acid*Age/sexCNSLiverColRDRenalOther
Hunter 1974, case 1NANA12y/FATHM(4y) PH(11y)+NPH(11y)AB, post-axial PD, CD
Bx(4y): BDA, CHF, CG
PSS(>11y)
Hunter 1974, case 2NANA9y/MATHSM(14 m) PH(6y)+NPH, CRFAB, CD
Bx(14 m): CHF
Thompson 1986, case 1NANA23y/FNAPH(8 m)+abn US: SK, CRF, ?NPH(21y)AB, CD
Bx(14y): BDA, CHF
PSS, splenectomy(14y)
Thompson 1986, case 2NANA18m/FEC, MCMBx/Ax(18 m): CHFAx(18 m): NPHAB, SZ, HR
lg CBdec:pneumonia(18 m)
lg 4th V
Verloes 1989, case 1†c.2498T>Cp.I833T32y/MCVH(CT)HSM(<1y) ELECRF, NPHAB, HR, club foot
c.G2556+1G>TSplBx(7,11y): BDA, CHF, CGBx(11y)Small stature
PSS(11y), dec: PH(32y)Diet
Verloes 1989, case 2†c.2498T>Cp.I833T37y/FCVH(CT)HSM(13y), PH(36)+LCRF, NPH HDHR
c.G2556+1G>TSplBx(11y): CHF, CHTx (20's)
PSS(30y)
Verloes 1989, case 3NANA8y/MDilated 4th V, MCM(CT)HSM(15 m)+CRF(8y), ?NPH
Bx(1,5y): BDA, CHF, CH
Wiesner 1992, case 1NANA34y/MCVHELE(34y)+Deaf
Bx(34y): BDA, CHF
Rx: ursodiol
Wiesner 1992, case 2NANA46y/FATPH(NA)NANAAx: NPH
Bx/Ax(46y): BDA, CHF
dec: PH(46y)
Lewis 1994, case 1NANA5y/FMTS(CT)HM(3 m),HSM(3y) PH(4y)++ (4 m)CRF(5y)dec: PH + CRF(5y)
Bx/Ax(3y): BDA, CHF, focal DPMAx; NPH
dec: PH(5y)
Lewis 1994, case 2NANA17m/MCVH(CT)HM(6 m)++ (12 m)EK ?NPH(17 m)AB, HR
Bx(1y): BDA, CHF
Gentile 1996, case 1†c.1769T>Cp.F590S16y/MCVHHSM(2y), ELE, PH(10y)
c.G1961-2A>CSplBx(7y, 10y): BDA, CHF
Tx(12,16y), dec: HCV hepatitis(16y)
Gentile 1996, case 2†c.1769T>Cp.F590S17y/MMTSHM(18 m), ELE, PH, HSP
c.G1961-2A>CSplBx(30 m): CHF
platelet transfusion PH, Rx
Kumar 1996, case 1NANA23y/FATHSM(21y), PH(22y), HSP(23y)+CRF(22y)
Bx(23y): BDA, CHFBx: NPH(23y)
PSS
Kumar 1996, case 2NANA6y/FCVH, elevation 4th VHM, ELE(5y)+
Barzilai 1998NANA19y/FMTSELE, HSM, PH, HSP(7y)+NPH(7y)CD
Bx(7y): BDA, CHF
Kirchner 2002NANA20y/FCVHELE, HM(9y), PH, HSP(20y)+
US(20y): liver nodules/fibrosis
Bx(11y): CHF, C regenerative nodules
Coppola 2002, case 1†c.579_80delAGp.G195IfsX13p.F590S10y/MMTSELE(8y), abn US(10y)
c.1769T>CBx(10y): BDA, CHF
Rx: ursodiol
Coppola 2002, case 2†c.579_80delAGp.G195IfsX133y/FMTSAbn US
c.1769T>Cp.F590SBx(3y): CHF
Rx: ursodiol
Coppola 2002, case 3NANA18y/MCVH(CT)PH(13y)EK(13y), ?NPHdec: PH(18y)
Bx(13y): CHF, CG
sclerotherapy
Herzog 2002NANA18y/FCVHELE, PH, HSP(8y)+CRF(12y)
Bx(8y): BDA, CHF
Tx(12y)
Gleeson 2004, case 3NANA7y/MMTSELE(3y), PH(5y)+EK, NC, NPH(5y)AB
Bx(5y): BDA, CHF
sclerotherapy
Dieterich 1980, case 1NANA6y/FCVH(CT)HM(5y)+CRF
Bx(5y): BDA, CHFBx(5y): NPH
dec: ESRD(6y)
Dieterich 1980, case 2NANA6y/FATPH(6y)+CRF, ?NPH
?Ax/Bx: CHF(6y)
dec: PH(6y)
Uemura 2005, case 1NANA38y/FATPH, ELE(18y), PH(22y), Bx(21y): BDA, CHF, PSS, splenectomy, Tx(28y)+CRF, ?NPH
HD(24y) Tx(28y)
Uemura 2005, case 2‡NANA21y/FMTSSM(10y)+EK, NC, ?NPH
Bx(10y): CHF
PSS
Brinkman 2004§NANA28y/MMTSELE, US(22y): fibrosis+NPH(22y)AB, HR, Burkitt lymphoma (ileal)
ESRD(25y)
Graber 2001, case 2NANA15m/MMTSHM(birth)++abn US(<15 m), NPH
Bx(<1y):CHF
Baala 2007 JS-661c.1538A>Gp.Y513C28wCVH(Ax)Ax(28w EGA): BDA, CHFNANARMC, ?NPHTermination
c.2315_23+4Splfetus
del13insGG
Baala 2007 JS-660c.1538A>Gp.Y513C30w fetusCVH(Ax)Ax(30w EGA): BDA, CHFNANARMC, ?NPHTermination
c.2315_23+4Spl
del13insGG
Baala 2007 JS-786c. 637C>Tp.R213C7y/MCVH(CT)“severe liver disease”EK, RMC, ?NPHAB
c. 2132A>Cp.D711A
Wolf 2007 A1183 II-1RPGRIP1L:Spl7y/MCVHPH(7y)EKAB, pituitary agenesis, abdominal myofibroblastic tumour
c.3497-2A>G?Bx(7y): CHFBx: NPH
?
WolfRPGRIP1L: c.1177G>Ap.E393K29y/MBx(29y): CHF+EK, SK, NPH
2007 F631 II-1??ESRD(21y)
Brancati 2009 COR32-1c.1115C>Ap.T372K6y/MMTSHM, BDA(MRI)+AB
c.2345A>Gp.H782RUnilateral renal agenesis
Brancati 2009 COR32-2c.1115C>Ap.T372K1y/MMTSELE+NA
c.2345A>Gp.H782R
Brancati 2009 COR71c.389C>Gp.P130R20y/FMTSHM, ELE+NPHHR, small stature
c.675G>Ap.W225XBx: CHFESRD
Brancati 2009 COR94c.1319G>Ap.R440Q3y/MMTSHM, ELE+AB, CD, HR, small stature
c.2182A>Gp.S728GBx: CHF
Brancati 2009 COR190c.G312+5G>ASpl9y/FMTSHM, ELE, BDANPH, CRFAB
c.2498T>Cp.I833TEC
Brancati 2009 COR191-1c.2460A>Cp.R820S9y/MMTSHM, ELENPH, ESRDAB, HR
??Bx: CHF
Brancati 2009 COR191-2c.2460A>Cp.R820SfetusCVHAx: CHFNAMKDPD
??EC
PKD238 Gunay-Aygun 2009c.224-2A>T c.1843T>Cp.C615R8y/MMTSELE(5y), HSM(7y)LK, EK(fetal)
SplBx(7y): BDA, CHFRMC(birth)
CRF, HTN
PKD271 Gunay-Aygun 2009c.1843T>Cp.C615R6y/FATELEMKD(fetal), CRF, HTN
c.1843T>Cp.C615R
PKD272 Gunay-Aygun 2009c.1843T>Cp.C615R10y/MMTSELEHTN, CRF, NPH
c.1843T>Cp.C615RBx(5y): BDA, CHFBx(8y): RMC
CG(5y)Tx(8y)
  • See table 1 for key to abbreviations.

  • All UW subjects had developmental delay/mental retardation, hypotonia and/or ataxia, oculomotor apraxia.

  • Age refers to age at last contact in years (y), months (m) or weeks gestation (w).

  • Laterality of manifestations is stated as either; R, right; L, left; or bilateral unless otherwise stated.

  • * All mutations are in MKS3 except for the two families in Wolf 2007 as noted.

  • also in Brancati et al39.

  • unpublished information C Clericuzio.

  • § also in Lindhout et al.60